由肠道微生物驱动的瘤免疫微环境调节优化了高级非小细胞肺癌中双重检查点封锁
Y Katayama1, A Fukuda2, R Inoue3
1Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
ESMO open
|February 17, 2026
概括
高肠道细菌多样性改善了非小细胞肺癌 (NSCLC) 患者的治疗结果,这些患者接受了伊皮利马布加尼沃马布 (I-N) 治疗. 肠道微生物组可以预测对双检查点阻塞疗法的反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 双检查点阻塞 (ipilimumab加nivolumab) 在晚期非小细胞肺癌 (NSCLC) 中显示出有效性,但益处仅限于一小部分患者.
- 肠道微生物对免疫反应的影响表明,在免疫检查点抑制剂的有效性方面可能发挥作用.
研究的目的:
- 调查肠道微生物特征与接受双重检查点封锁的NSCLC患者治疗疗效之间的关联.
- 探索肠道微生物群多样性,瘤透淋巴细胞 (TILs) 和临床结果之间的关系.
主要方法:
- 一项前性研究,50名NSCLC患者接受伊皮利马布加尼沃马布 (I-N) 治疗,有或没有化疗.
- 从便样本评估肠道微生物群的多样性和组成,并通过多重免疫光学评估TILs.
- 分析与微生物群和治疗相关的无进展生存 (PFS),总生存 (OS) 和客观反应率.
主要成果:
- 高肠道微生物群多样性与仅接受I-N的患者的改善结果和增加的CD8+TIL透 (特别是PD-1+CD8+TIL) 相关联.
- 单独使用I-N的响应者表现出短链脂肪酸 (SCFA) 生产细菌的丰富和有利的代谢途径.
- 对于I-N加化疗,肠道微生物群多样性和疗效之间没有发现任何关联;之前使用抗生素与更短的PFS和OS有关.
结论:
- 肠道微生物群多样性和SCFA产生细菌与NSCLCI-N疗法的效率提高有关.
- 基线肠道微生物群的多样性可能会识别出与单独的I-N相比,I-N加化疗更受益的患者.
- 肠道微生物群在NSCLC双检查点阻塞疗法中显示出作为个性化药物的生物标志物的潜力.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.9K
08:42Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
2.4K
相关概念视频
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
